3 news items
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
ANTX
VBIV
VIR
22 Mar 24
as of December 31, 2022. The decrease was primarily due to payout of daily operations and research and development activities
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
VIR
5 Mar 24
of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
VIR
22 Feb 24
.
On February 21, 2024, the Company and GSK terminated their collaboration to research, develop and commercialize the Company's
- Prev
- 1
- Next